山外山(688410.SH):公司目前連續性血液淨化設備(CRRT)市場佔有率排名第一
格隆匯12月22日丨山外山(688410.SH)近期在接待機構投資者調研時表示,根據相關數據表明,公司目前連續性血液淨化設備(CRRT)市場佔有率排名第一,公司該設備擁有14種治療模式,是目前市場上功能最強大,適應症範圍最廣的CRRT設備。
隨着國家政策的支持力度加大,重症能力建設以及國產替代步伐的加快,使得國產高端醫療器械的需求快速增加。此外,由於我國人口老齡化加劇及三高人羣數量增長,使得未來較長的時間裏CRRT將維持較高水平的市場需求。
隨着公司上市後的技術研發力度不斷加強,產品技術水平和品質將不斷提升,市場核心競爭力將不斷增強,有助於公司在血液淨化行業保持領先地位,將進一步提高公司CRRT的市場佔有率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.